Table 1.
Patient Characteristics at Nephrectomy by Metastatic Status at Diagnosis and by Metastasectomy Status
| Synchronous Metastasis at Diagnosis | Asynchronous Metastasis at Diagnosis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| All | Metastasectomy | No Metastasectomy |
All | Metastasectomy | No Metastasectomy |
||||
| Patient Characteristics | N (%) | N (%) | N (%) | P-Value | N (%) | N (%) | N (%) | P-Value | |
| All Patients | 56 (100%) | 30 (100%) | 26 (100%) | 24 (100%) | 10 (100%) | 14 (100%) | |||
| Age, years - median (IQR) | 54 (49, 64) | 54 (47, 64) | 55 (49, 63) | 0.83 | 53 (49, 59) | 52 (48, 60) | 54 (49, 58) | 0.97 | |
| Gender | 0.33 | 0.10 | |||||||
| Female | 22 (39%) | 10 (33%) | 12 (46%) | 12 (50%) | 3 (30%) | 9 (64%) | |||
| Male | 34 (61%) | 20 (67%) | 14 (54%) | 12 (50%) | 7 (70%) | 5 (36%) | |||
| Race Ethnicity | 0.47 | 0.81 | |||||||
| White | 42 (75%) | 25 (83%) | 17 (65%) | 17 (71%) | 8 (80%) | 9 (64%) | |||
| Black | 2 (4%) | 1 (3%) | 1 (4%) | 2 (8%) | 0 (0%) | 2 (14%) | |||
| Hispanic | 10 (18%) | 3 (10%) | 7 (27%) | 3 (13%) | 1 (10%) | 2 (14%) | |||
| Other | 2 (4%) | 1 (3%) | 1 (4%) | 2 (8%) | 1 (10%) | 1 (7%) | |||
| Smoking History | 0.25 | 0.12 | |||||||
| Yes | 30 (55%) | 14 (47%) | 16 (64%) | 14 (58%) | 4 (40%) | 10 (71%) | |||
| No | 24 (44%) | 15 (50%) | 9 (36%) | 10 (42%) | 6 (60%) | 4 (29%) | |||
| Unknown | 1 (2%) | 1 (3%) | 0 (0%) | ||||||
| BMI, kg/m2 - median (IQR) | 25 (23, 29) | 25 (23, 31) | 25 (22, 28) | 0.20 | 29 (26, 36) | 27 (24, 33) | 31 (27, 40) | 0.07 | |
| ECOG Performance Status | 0.36 | 0.64 | |||||||
| 0 | 13 (23%) | 6 (20%) | 7 (27%) | 6 (25%) | 3 (30%) | 3 (21%) | |||
| 1 | 39 (70%) | 23 (77%) | 16 (62%) | 17 (71%) | 7 (70%) | 10 (71%) | |||
| >=2 | 4 (7%) | 1 (3%) | 3 (12%) | 1 (4%) | 0 (0%) | 1 (7%) | |||
| Charlson - median (IQR) | 6 (6, 6) | 6 (6, 6) | 6 (6, 6) | 0.25 | 3 (2, 6) | 2 (2, 6) | 3 (2, 6) | 0.66 | |
| Pathologic T Stage | 0.25 | 0.11 | |||||||
| T1/T2 | 9 (16%) | 7 (23%) | 2 (8%) | 6 (26%) | 3 (33%) | 3 (21%) | |||
| T3 | 39 (70%) | 20 (67%) | 19 (73%) | 11 (48%) | 6 (67%) | 5 (36%) | |||
| T4 | 8 (14%) | 3 (10%) | 5 (19%) | 6 (26%) | 0 (0%) | 6 (43%) | |||
| Clinical N Stage at Diagnosis |
0.65 | >0.99 | |||||||
| cN0 | 51 (91%) | 28 (93%) | 23 (88%) | 20 (83%) | 8 (80%) | 12 (86%) | |||
| cN1 | 5 (9%) | 2 (7%) | 3 (12%) | 4 (17%) | 2 (20%) | 2 (14%) | |||
| Pathologic N Stage | 0.89 | >0.99 | |||||||
| pN0 | 16 (29%) | 8 (27%) | 8 (31%) | 11 (46%) | 4 (40%) | 7 (50%) | |||
| pN1 | 15 (27%) | 9 (30%) | 6 (23%) | 9 (38%) | 4 (40%) | 5 (36%) | |||
| pNx | 25 (45%) | 13 (43%) | 12 (46%) | 4 (17%) | 2 (20%) | 2 (14%) | |||
| Nephrectomy Side | 0.14 | 0.40 | |||||||
| Left | 33 (59%) | 15 (50%) | 18 (69%) | 17 (71%) | 8 (80%) | 9 (64%) | |||
| Right | 23 (41%) | 15 (50%) | 8 (31%) | 7 (29%) | 2 (20%) | 5 (36%) | |||
| Nephrectomy Histology | >0.99 | >0.99 | |||||||
| Clear cell | 45 (80%) | 24 (80%) | 21 (81%) | 19 (79%) | 8 (80%) | 11 (79%) | |||
| Other | 11 (20%) | 6 (20%) | 5 (19%) | 5 (21%) | 2 (20%) | 3 (21%) | |||
| % Sarcomatoid | 0.02 | 0.84 | |||||||
| 1–24 | 26 (50%) | 20 (67%) | 6 (27%) | 16 (76%) | 5 (63%) | 11 (85%) | |||
| 25–49 | 14 (27%) | 4 (13%) | 10 (45%) | 1 (5%) | 1 (13%) | 0 (0%) | |||
| 50–74 | 7 (13%) | 3 (10%) | 4 (18%) | 2 (10%) | 1 (13%) | 1 (8%) | |||
| 75–99 | 5 (10%) | 3 (10%) | 2 (9%) | 2 (10%) | 1 (13%) | 1 (8%) | |||
| Systemic Therapy (At Any Time) |
0.36 | 0.02 | |||||||
| No | 9 (16%) | 6 (21%) | 3 (12%) | 3 (13%) | 3 (33%) | 0 (0%) | |||
| Yes | 46 (84%) | 23 (79%) | 23 (88%) | 20 (87%) | 6 (67%) | 14 (100%) | |||
P-Values are calculated using Pearson’s Chi-Square test, using Fisher’s exact calculations when needed for small sample sizes. Patients with unknown or missing values are not included in the comparison.